End the Block on Generic Veterinary Medications
90 million American households own pets. Their medications cost 10–15× more than the human equivalent — not because of science, but because pharmaceutical manufacturers have used exclusive distribution agreements to block FDA-approved generics from reaching veterinary shelves. The FTC has documented the practice. Legislation exists to fix it. It just needs professional advocacy to get it across the finish line.
What's happening
Your dog's Apoquel costs $4 a pill. The same compound, approved for human use, is available in generic form for under $0.30. This is not a manufacturing problem. It is a lobbying problem.
Pharmaceutical manufacturers have used exclusive distribution agreements with veterinary suppliers to ensure that FDA-approved human generics never reach veterinary shelves. The practice is legal — because the industry has successfully lobbied to keep it that way.
"The Animal Health Institute spent $3.2 million lobbying Congress last year to protect the exclusivity arrangements that keep generic veterinary drugs off the market. There is currently no organized counter-lobbying effort on behalf of pet owners."
The Animal Generic Drug User Fee Act would create a pathway for FDA-approved generics to reach the veterinary market. It has bipartisan support in principle. What it lacks is the professional advocacy to push it through committee and onto the floor.
Who this affects
Why now
The Animal Generic Drug User Fee Act is currently in the Senate Health, Education, Labor & Pensions Committee. The committee has jurisdiction and the votes may be there — but without sustained professional pressure, it will not move to the floor before the session ends.
A funded campaign can change that. A registered lobbyist with direct relationships in the HELP Committee can accelerate the timeline, identify the right pressure points, and keep the bill moving. That is exactly what the other side has been doing for years. Now pet owners can too.
What your money funds
A six-month retainer with a registered lobbying firm that has active relationships in the Senate HELP Committee and the FDA. Here is exactly what that firm will do:
Month 1–2: Coalition building
Identify and brief sympathetic Senate and House offices. Coordinate with veterinary associations, consumer groups, and pet industry stakeholders who share an interest in generic access. File initial LDA registration and disclosure.
Month 3–4: Committee engagement
Direct engagement with HELP Committee staff on the Animal Generic Drug User Fee Act. Prepare and deliver a one-pager and technical briefing document. Identify amendment opportunities if the bill needs to be modified to advance.
Month 5–6: Floor strategy
Work with committee leadership offices on a path to floor consideration. Coordinate with House counterparts on parallel track. Prepare constituents for targeted outreach to undecided members.
VOICE funds professional effort, not guaranteed outcomes. No lobbyist — however experienced — can promise a legislative result. What we can promise is a registered professional working every available lever for six months. Monthly activity reports will be filed publicly and shared with all contributors.